• wpml-ls-flag
  • wpml-ls-flag
Support

News

Ortivus AB (publ) quarterly report for the period January – March 2021

Ortivus is growing and attracting additional distributors. Operating cash flow improved to 5.1 MSEK during the first quarter 2021.

Highlights Jan – Mar 2021

  • Ortivus has signed a distribution agreement with Bexen Cardio Italia Srl to create new marketing and sales channels in Italy.

Jan – Mar 2021

  • Net sales amounted to 23.5 (20.2) MSEK, which is an increase in sales of 17%
  • Operating cash flow amounted to 5.1 (3.2) MSEK
  • Operating profit amounted to 1.7 (1.1) MSEK
  • Profit after tax was 1.7 (1.1) MSEK
  • Earnings per share after tax and before and after dilution amounted to 0.04 (0.02) SEK
Amount in KSEK Jan-Mar 2021 Jan-Mar 2020 Jan-Dec 2020
Net sales 23 542 20 161 107 582
Gross margin, % 50.1% 44.4% 36.2%
Operating cash flow 5 104 3 166 11 895
Operating profit 1 733 1 112 11 392
Operating margin, % 7.4% 5.5% 10.5%

Contacts

For further information, please contact

Reidar Gårdebäck, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, medical technology solutions for a safer and more efficient
healthcare. The company was founded in 1985 and is today a leading provider of mobile digital
solutions for prehospital care, worldwide. Ortivus' products are based on in-depth expertise
in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm and the company has, since 1998, a wholly-owned subsidiary based in the United Kingdom.

MobiMed is a modular platform that currently is used by over 12 000 paramedics in over 2 700 emergecy vechicles. The platform consists of a monitor that in real-time measures, monitors and shares patients'
vital parameters, such as, ECG, blood pressure and blood oxygenation. The system also consists
of an electronic patient record for decision support, collection of patient data and clinical documentation.
MobiMed has a total weight of 2.5kg and is created to function in a demanding environment and out in
the field. The two-way communication supports telemedicine consulting with clinical experts while patient data is seamlessly integrated into the medical records at the hospitals and primary care centers. MobiMed saves time and helps healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-04-27 08:30 CEST.

Attachments

Ortivus Quarterly Report Jan Mar 2021

Ortivus Quarterly Report Jan Mar 2021